• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤坏死因子对小鼠肿瘤脉管系统的毒性作用。

Toxic effect of tumor necrosis factor on tumor vasculature in mice.

作者信息

Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, Urushizaki I

机构信息

Department of Internal Medicine, Sapporo Medical College, Japan.

出版信息

Cancer Res. 1988 Apr 15;48(8):2179-83.

PMID:3349488
Abstract

Stereoscopic observation via an implanted sight glass in mice bearing transplanted methylcholanthrene-induced A-cells showed tumorivascular hemorrhage at 1-2 h after tumor necrosis factor (TNF) administration, congestion at 4-6 h, and hemorrhage, congestion, and blood circulation blockage at 24 h. Histological examination after TNF administration to mice bearing similar methylcholanthrene-induced A-cell transplants showed thrombus formation in the tumor vasculature at 4 h and thereafter. Suppression of this thrombus formation with heparin had no apparent influence on the necrotic response, tumor growth inhibition or complete cure rate following TNF administration to mice bearing the methylcholanthrene-induced A-cell tumors. The results suggest that direct toxicity of TNF on tumor vasculature is a factor in the overall antitumor mechanism of TNF.

摘要

通过植入视镜对携带甲基胆蒽诱导的A细胞移植瘤的小鼠进行立体观察,结果显示,给予肿瘤坏死因子(TNF)后1 - 2小时肿瘤血管出现出血,4 - 6小时出现充血,24小时出现出血、充血和血液循环阻断。对携带类似甲基胆蒽诱导的A细胞移植瘤的小鼠给予TNF后进行组织学检查,结果显示4小时及之后肿瘤血管中形成血栓。用肝素抑制这种血栓形成,对给予TNF的携带甲基胆蒽诱导的A细胞肿瘤的小鼠的坏死反应、肿瘤生长抑制或完全治愈率没有明显影响。结果表明,TNF对肿瘤血管的直接毒性是TNF整体抗肿瘤机制中的一个因素。

相似文献

1
Toxic effect of tumor necrosis factor on tumor vasculature in mice.肿瘤坏死因子对小鼠肿瘤脉管系统的毒性作用。
Cancer Res. 1988 Apr 15;48(8):2179-83.
2
[The mechanism of action of tumor necrosis factor (TNF) on tumor vascularity--study using a transparent chamber].[肿瘤坏死因子(TNF)对肿瘤血管的作用机制——使用透明室的研究]
Gan To Kagaku Ryoho. 1987 Dec;14(12):3337-43.
3
Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.用肿瘤坏死因子-α诱导药物5,6-二甲基呫吨酮-4-乙酸进行治疗可增强RIF-1小鼠肿瘤光动力疗法的抗肿瘤活性。
Cancer Res. 2003 Nov 15;63(22):7584-90.
4
Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.重组人肿瘤坏死因子对小鼠和人类肿瘤的治愈及部分消退
Cancer Res. 1986 Nov;46(11):5687-90.
5
Intratumoral tumor necrosis factor induction in tumor-bearing mice by exogenous/endogenous tumor necrosis factor therapy as compared with systemic administration of various biologic response modifiers.
Mol Biother. 1991 Dec;3(4):224-30.
6
Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.肿瘤坏死因子α与二乙烯基醚和马来酸酐共聚物偶联物对小鼠实体瘤的抗肿瘤活性。
Cancer Res. 1998 Jan 15;58(2):290-5.
7
Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia.重组人肿瘤坏死因子与热疗的协同细胞毒性和抗肿瘤作用。
Cancer Res. 1988 Feb 1;48(3):650-3.
8
Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.重组人肿瘤坏死因子-α:抗肿瘤活性间接模式的证据
Cancer Res. 1987 Jul 15;47(14):3707-11.
9
[Induction of tumor necrosis factor (TNF) in tumor-bearing mice].[荷瘤小鼠中肿瘤坏死因子(TNF)的诱导]
Gan To Kagaku Ryoho. 1984 Jul;11(7):1369-78.
10
Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions.
Anticancer Res. 1998 Sep-Oct;18(5D):3957-64.

引用本文的文献

1
Gold and Silver Nanoparticles Efficiently Modulate the Crosstalk Between Macrophages and Cancer Cells.金纳米颗粒和银纳米颗粒有效调节巨噬细胞与癌细胞之间的串扰
Int J Nanomedicine. 2025 Apr 15;20:4777-4802. doi: 10.2147/IJN.S508171. eCollection 2025.
2
Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.使用免疫细胞因子激发抗肿瘤免疫反应:临床前与临床概述
Pharmaceutics. 2024 Jul 24;16(8):974. doi: 10.3390/pharmaceutics16080974.
3
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions.
一种同时融合白细胞介素-2和肿瘤坏死因子的靶向成纤维细胞活化蛋白的抗体选择性定位于肿瘤病变部位。
Antibodies (Basel). 2023 Apr 14;12(2):29. doi: 10.3390/antib12020029.
4
Multi-omics consensus portfolio to refine the classification of lung adenocarcinoma with prognostic stratification, tumor microenvironment, and unique sensitivity to first-line therapies.多组学共识组合用于优化肺腺癌的分类,包括预后分层、肿瘤微环境以及对一线治疗的独特敏感性。
Transl Lung Cancer Res. 2022 Nov;11(11):2243-2260. doi: 10.21037/tlcr-22-775.
5
Tumor Necrosis Factor: What Is in a Name?肿瘤坏死因子:名称中有何含义?
Cancers (Basel). 2022 Oct 27;14(21):5270. doi: 10.3390/cancers14215270.
6
RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α-XBP1s pathway.RCN1通过IRE1α-XBP1s途径激活c-MYC信号通路,从而诱导肝细胞癌对索拉非尼产生耐药性并促进其恶性发展。
Cell Death Discov. 2021 Oct 18;7(1):298. doi: 10.1038/s41420-021-00696-6.
7
Targeting apoptosis in cancer therapy.靶向细胞凋亡治疗癌症。
Nat Rev Clin Oncol. 2020 Jul;17(7):395-417. doi: 10.1038/s41571-020-0341-y. Epub 2020 Mar 23.
8
CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans.使用高分子量葡聚糖的 CEST MRI 监测肿瘤对血管破坏治疗的反应。
Magn Reson Med. 2019 Oct;82(4):1471-1479. doi: 10.1002/mrm.27818. Epub 2019 May 20.
9
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.抗体-细胞因子融合蛋白:一类新型生物制药,用于癌症和慢性炎症的治疗。
N Biotechnol. 2019 Sep 25;52:42-53. doi: 10.1016/j.nbt.2019.04.002. Epub 2019 Apr 13.
10
Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.释放内源性 TNF-α作为癌症免疫疗法。
J Transl Med. 2018 Aug 31;16(1):242. doi: 10.1186/s12967-018-1611-7.